INTENSITY THERAPEUTICS, INC. 8-K

What Happened
On March 5, 2026, Intensity Therapeutics, Inc. (INTS) received a letter from The Nasdaq Stock Market confirming the company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the $1.00 minimum bid price requirement). Nasdaq found the company maintained a minimum closing bid of $1.00 per share for 10 consecutive business days from February 19, 2026 through March 4, 2026, and stated the matter is now closed. The company filed an 8-K on March 6, 2026 and issued a press release the same day (Exhibit 99.1).

Key Details

• Nasdaq compliance letter received March 5, 2026 confirming restoration of compliance.
• The qualifying period was 10 consecutive business days from Feb 19, 2026 to Mar 4, 2026 (minimum $1.00 closing bid).
• Background: Nasdaq first notified the company of non-compliance on June 6, 2025 (180-day cure period to Dec 3, 2025) and granted an additional 180-day extension on Dec 4, 2025 (extended cure period to June 1, 2026).
• Company announced the regained compliance via press release on March 6, 2026 (attached as Exhibit 99.1).

Why It Matters
Regaining compliance removes the immediate risk of delisting tied to the minimum bid price deficiency and preserves the company’s Nasdaq listing, which supports trading liquidity and investor access. For investors, this is a procedural but material development: it addresses a past listing deficiency without reporting any changes to financial results or management.